I
t is well known that antimicrobial resistance parallels the consumption of antimicrobial therapy. In developing countries, antimicrobial resistance is high and rising. 1, 2 Unique antibiotic resistance problems such as pan-resistant Acinetobacter baumanii are thought to be of particular concern in the Middle East. 3 In addition, the Middle East is the intersection between developed and developing countries and thus the region is exposed to resistant bacteria. 2 Many studies have addressed the issue of antimicrobial resistance in Saudi Arabia. Resistance rates are variable depending on the organism and the geographic area of the study. In addition, many factors contribute to the development of resistance throughout the world and specifically in the Middle East, including Saudi Arabia. 2 These factors include inappropriate prescriptions, which were found to range between 24% and 80% for patients attending community hospitals. 4, 5 However, there are no data on antimicrobial usage based on the concept of the defined daily dose (DDD) Information on the annual usage of intravenous systemic antimicrobial agents was obtained from the pharmacy register of the annual medication utilization from 2006 to 2008. The pharmacy keeps records and infor-mation about all dispensed medications on a monthly and yearly basis. The information and data included the numbers of drugs dispensed by form, type, and route of administration. Data on antibiotics were determined through the number of packages and doses from the hospitals' pharmacy database for each year. Intravenous systemic antimicrobial agents are equivalent to group J01 of the Anatomical Therapeutic Chemical (ATC) classification system from the WHO Collaborating Centre for Drug Statistics Methodology. 7 To estimate antibiotic usage, the total numbers of grams of each antibiotic used were summed for each year, and were divided by the WHO-assigned DDD, thus, estimating the number of days of antibiotic therapy (g/day). DDDs were expressed per 100 patient-days to control the differences of hospital census.
8 DDDs/100 patient-days=(annual consumption of antibacterial
Other studies report consumption as DDDs per 1000 patient-days. 9 The calculation of DDDs/100 patient-days was done using ABC-Calc "Antibiotic Consumption Calculator," version 3.1 (2006) . 10 The change in antibiotic usage was compared between 2006 and 2008, and was expressed as a percentage and for this change a P values <.05 were considered statistically significant.
RESULTS
During the study period from 2006 to 2008, the total parenteral antibiotics, ciprofloxacin was the most commonly used intravenous antibiotic (67.6%), followed by ceftriaxone (6%), cefazolin (5%) and imipenem-enzyme inhibitor (4.3%). (Figure 1) . This increase did not reach statistical significance but a linear trend was observed with R 
DISCUSSION
Fluoroquinolone resistance is an emerging problem in many countries including Saudi Arabia. Hospitalacquired isolates of Klebsiella pneumoniae showed 23% ciprofloxacin resistance 11 and Escherichia coli showed a rate of 46% resistance. 12 This resistance could be partially explained by increasing the use of fluoroquinolones, not only in the hospital, but also in the community. Thus, the findings in this study of a significant usage of intravenous ciprofloxacin should direct efforts to optimize the usage of this medication. Although the P value was not significant, a linear trend was observed with R 2 =0.8768. Thus, the finding is indicative of a preferential increase in the use of ciprofloxacin during the study period. In a Danish study, a significant increase in the total consumption of oral ciprofloxacin was linked to the introduction of generic ciprofloxacin, and this in turn correlated with ciprofloxacin resistance in urinary isolates of E coli. 13 One reason for increased usage of intravenous antimicrobial therapy may be related to the practice of the use of combination therapy for hospitalized patients.
The main carbapenem being used was an imipenemenzyme inhibitor and the rate of utilization was higher than the reported rate from other studies.
14 The finding in our study is consistent with those from other countries. 15 Vancomycin utilization remains relatively low at about 1.4-2.9 DDD/100 patient-days. This rate falls within the 10% to 50% of the National Healthcare Safety Network (NHSN) data 16 and is close to the mean utilization of vancomycin of 1.9/100 bed-days in a study from 29 public hospitals and private clinics 17 This finding may explain the low prevalence of vancomycin-resistant enterococci (VRE) in Saudi Arabia. In a study of 4276 patients from a tertiary care referral hospital, VRE was identified in only six (0.14%) patients. 18 Our study has a few limitations. First, we included only intravenous antimicrobial therapy in the results, which was related to the fact that the data could not be separated for outpatient and inpatient for oral antimicrobial agents. Second, the data represented one hospital in the Saudi Arabia and thus may not be a representative of the whole country. Third, similar to what was noted previously, 19 the data included children and adults; however, DDD are only defined for adults by the WHO Collaborating Centre for Drug Statistics Methodology. Fourth, the actual usage of all (intravenous and oral) systemic antimicrobials could not be calculated in this study. To allow for comparison with benchmarking data such as the NHSN 16 it is important to have specific unit antimicrobial consumption data. 20 Such data would be more informative if it had been correlated to the resistance pattern in each unit. 9, 21 Despite these limitations, the study is the first from Saudi Arabia to shed light on antimicrobial utilization using the DDD concept. The discrepancy in antimicrobial utilization between different hospitals is a reflection of different policies at diverse institutions. In future studies, it is important to include education and an antimicrobial stewardship program to particularly control the use of quinolones. In addition, we need to assess antibiotic indication, duration, and to include oral antimicrobial therapy in the inpatient as well as the outpatient setting.
